SCHEMBL10165816

SCHEMBL10165816

CC(C)(C)OC(=O)N1CCC(NC(=N)N)CC1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EPHX1 P07099 1/20 0.65
ALDH1A1 P00352 3/20 0.50
CA12 O43570 1/20 0.50
CA1 P00915 1/20 0.50
CA2 P00918 1/20 0.50
CA9 Q16790 1/20 0.50
L3MBTL1 Q9Y468 2/20 0.49
NPC1 O15118 1/20 0.49
MAPT P10636 1/20 0.49
MAPK1 P28482 1/20 0.49
HTT P42858 1/20 0.49
RAB9A P51151 1/20 0.49
HPGD P15428 1/20 0.49
EPHX2 P34913 3/20 0.48
PARP1 P09874 1/20 0.47
RECQL P46063 1/20 0.47
GPR119 Q8TDV5 2/20 0.46
PTPN2 P17706 1/20 0.46
PTPN1 P18031 1/20 0.46
PTPN6 P29350 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL538324 0.98 EPHX1 (0.63) EPHX1ALDH1A1CA12CA1CA2
SCHEMBL4196587 0.91 EPHX1 (0.55) EPHX1ALDH1A1PARP1HDAC4
SCHEMBL14450277 0.88 EPHX1 (0.68) EPHX1ALDH1A1CA12CA1CA2
SCHEMBL3911344 0.85 EPHX1 (0.65) EPHX1ALDH1A1CA12CA1CA2
SCHEMBL17093544 0.84 EPHX1 (0.63) EPHX1ALDH1A1CA12CA1CA2
Hydrochloric Acid SCHEMBL29854456 0.83 EPHX1 (0.44) EPHX1CA1CA2HPGDPARP1
SCHEMBL23602645 0.83 USP30 (0.54) EPHX1ALDH1A1CA12CA1CA2
SCHEMBL10165886 0.83 USP30 (0.54) EPHX1ALDH1A1CA12CA1CA2
SCHEMBL10205689 0.83 USP30 (0.54) EPHX1ALDH1A1CA12CA1CA2
SCHEMBL2014950 0.83 EPHX1 (0.70) EPHX1ALDH1A1CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8349827-B2 Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds ARQULE, INC. (US) 2013-01-08 US disclosed
US-8349827-B2 Substituted dipyrido-pyrimido-diazepine and benzo-pyrido-pyrimido compounds ARQULE, INC. (US) 2013-01-08 US disclosed
US-8178672-B2 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase ARQULE, INC. (US) 2012-05-15 US disclosed
US-8178672-B2 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 MAP kinase ARQULE, INC. (US) 2012-05-15 US disclosed
EP-2258704-A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase ArQule, Inc. (US) 2010-12-08 EP disclosed
US-20100249108-A1 SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20090136499-A1 RAF Inhibitors and Uses Thereof ARQULE, INC. (US) 2009-05-28 US disclosed
US-20090136499-A1 RAF Inhibitors and Uses Thereof ARQULE, INC. (US) 2009-05-28 US disclosed
US-20090111985-A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase ARQULE, INC. 2009-04-30 US disclosed
US-20090111985-A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase ARQULE, INC. 2009-04-30 US disclosed
US-7501430-B2 e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders ARQULE, INC. (US) 2009-03-10 US disclosed
US-7501430-B2 e.g. 3-{5-[2-({(3R)-1-[(4-chlorophenyl)sulfonyl]piperidin-3-yl}amino)pyrimidin-4-yl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl carbamate; antiproliferative, anticarcinogenic agent; cell proliferative disorders ARQULE, INC. (US) 2009-03-10 US disclosed
US-20070281955-A1 RAF inhibitors and their uses ARQULE, INC. 2007-12-06 US disclosed
US-20070281955-A1 RAF inhibitors and their uses ARQULE, INC. 2007-12-06 US disclosed
WO-2007123892-A2 RAF INHIBITORS AND THEIR USES ARQULE INC. (US) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249108-A1 SUBSTITUTED DIPYRIDO-PYRIMIDO-DIAZEPINE AND BENZO-PYRIDO-PYRIMIDO COMPOUNDS PDXK, DPYD, DHFR EPHX1 576/4885ALDH1A1 873/4885CA12 3725/4885
US-20070281955-A1 RAF inhibitors and their uses BRAF, RAF1, ARAF EPHX1 2263/4885ALDH1A1 1902/4885CA12 4303/4885
US-20090111985-A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase MAPK1, MAPK14, MAPK15 EPHX1 1742/4885ALDH1A1 2858/4885CA12 4763/4885
US-20090136499-A1 RAF Inhibitors and Uses Thereof BRAF, RAF1, ARAF EPHX1 2191/4885ALDH1A1 1746/4885CA12 4235/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.